Strategies for maximizing clinical effectiveness in the treatment of schizophrenia

Journal of Psychiatric Practice

Volumn 12, Issue 6, 2006, Pages 348-363

  Tandon, Rajiv ^a   Targum, Steven D ^b   Nasrallah, Henry A ^c   Ross, Ruth ^d  

^a Florida Department of Children and Families   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d Ross Editorial   (United States)

Author keywords

Clinical effectiveness; Disease burden; Health monitoring; Schizophrenia; Side effects; Stigma; Treatment burden

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; CHRONIC DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; CONVALESCENCE; DEPRESSION; DIABETES MELLITUS; DYSKINESIA; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; FAMILY THEORY; FAMILY THERAPY; GROUP THERAPY; HEALTH CARE COST; HEALTH CARE DELIVERY; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; LEADERSHIP; LIFESTYLE; METABOLIC DISORDER; MOBILIZATION; NEGATIVE SYNDROME; PATIENT MONITORING; PSYCHIATRIST; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL ENVIRONMENT; PSYCHOTHERAPY; QT PROLONGATION; QUALITY OF LIFE; RELIABILITY; RESPONSIBILITY; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SKILL; SOCIAL ASPECT; SOCIAL SUPPORT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT PLANNING; WEIGHT GAIN;

ADAPTATION, PSYCHOLOGICAL; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; COST OF ILLNESS; DELIVERY OF HEALTH CARE; HEALTH PLANNING; HEALTH PROMOTION; HEALTH STATUS; HUMANS; MENTAL HEALTH SERVICES; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SOCIAL SUPPORT; STEREOTYPING; TREATMENT OUTCOME; UNITED STATES;

EID: 33751548088     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200611000-00003     Document Type: Review

References (130)

1. Anthony WA. Recovery from mental illness: The guiding vision of the mental health service system in the 1990's. Psychosocial Rehabilitation Journal 1993;16:11-23.
2. President's New Freedom Commission on Mental Health. Achieving the promise: Transforming mental health care in America: Final report. July 2003 (http://www.mentalhealth-commission.gov/reports/reports.htm).
3. Jibson MD, Glick ID, Tandon R. Schizophrenia and other psychotic disorders. Focus 2004;11:17-30.
4. Lieberman JA, Murray RM. Comprehensive care of schizophrenia: A textbook of clinical management. London: Martin Dunitz Ltd., 2000.
5. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004;161(2 Suppl):1-56.
6. Kane JM, Leucht S, Carpenter D. Expert consensus guideline series: Optimizing pharmacological treatment of psychotic disorders. J Clin Psychiatry 2003;64(suppl 12):1-100.
7. National Institute of Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance #43, London, 2002; www.nice.org.uk.
8. Nasrallah HA, Targum SD, Tandon R, et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 2005;56:273-82.
9. Liberman RP, Kopelowicz A, Ventura J, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002;14:256-72.
10. Liberman RP, Hilty DM, Drake RE, et al. Requirements for multidisciplinary teamwork in psychiatric rehabilitation. Psychiatr Serv. 2001;52:1331-42.
11. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-46.
12. Ho B-C, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am J Psychiatry 1998;155:1196-201.
13. Volavka J. The neurobiology of violence. Washington, DC, American Psychiatric Press; 2002.
14. Tandon R. Suicidal behavior in schizophrenia. Exp Rev Neurotherapeutics 2005;5:25-9.
15. Resnick SG, Rosenheck RA, Lehman AF. An exploratory analysis of correlates of recovery. Psychiatr Services 2004;55: 540-7.
16. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophr Res 2005;79:145-55.
17. Tandon R. Avoiding EPS is key to realizing "atypical" benefits. Current Psychiatry 2006;5:35-45.
18. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
19. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-8.
20. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
21. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26.
22. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
23. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
24. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10.
25. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-22.
26. Jones PB, Davies L, Barnes TR, et al. Randomized controlled trial of effect on quality of life of second-generation versus first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006;63:1079-87.
27. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715-23.
28. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: What does CATIE tell us? Parts 1 and 2. International Drug Therapy Newsletter 2006;41:51-8;67-74.
29. Duan N, Kraemer HC, Mintz J. Antipsychotic drugs and schizophrenia: Letter to the editor and authors' reply. N Engl J Med 2006;354:299-300.
30. Tandon R, Nasrallah HA. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses. Arch Gen Psychiatry 2006;63:935-7.
31. Kane JM. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J Clin Psychiatry 2006;67:831-2.
32. Constantine RJ, Richard SM, Surles RC, et al. Optimizing pharmacotherapy of schizophrenia: Tools for the psychiatrist. Current Psychosis and Therapeutics Reports 2006;4:5-11.
33. Turkington D, Dudley R, Warman DM, et al. Cognitive-behavioral therapy for schizophrenia: A review. J Psychiatr Pract 2004;10:5-16.
34. Wykes T. Psychological treatment for voices in psychosis. Cognit Neuropsychiatry 2004;9:25-41.
35. Durham RC, Chambers JA, Power KG, et al. Long-term outcome of cognitive behavior therapy clinical trials in Central Scotland. Health Technol Assess 2005;9:1-174.
36. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry 2006;163:365-73.
37. Kissling W, ed. Guidelines for neuroleptic relapse prevention in schizophrenia. Heidelberg: Springer Verlag; 1991.
38. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Arch Gen Psychiatry 1995;52:173-88.
39. Greden JF, Tandon R. Long-term treatment for lifelong disorders? Arch Gen Psychiatry 1995;52:197-200.
40. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
41. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.
42. Kane J, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002;159:554-60.
43. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(suppl 5):9-14.
44. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone: Analysis of long-term efficacy. J Psychopharmacol 2005;19(5 Suppl):15-21.
45. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res 1998;32:243-50.
46. McFarlane W, Lukens E, Link B, et al. Multiple family groups and psychoeducation in the treatment of schizophrenia. Arch Gen Psychiatry 1995;52:679-87.
47. Pitschel-Walz G, Leucht S, Bauml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia: A meta-analysis. Schizophr Bull 2001;27:73-92.
48. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2002;(2):CD002831.
49. Hogarty GE, Kornblith SJ, Greenwald D, et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: Description of study and effects on relapse rates. Am J Psychiatry 1997;154:1504-13.
50. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. Cochrane Database Syst Rev 2000;(2):CD001089.
51. Drake RE, Essock SM, Shaner A, et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv 2001;52:469-76.
52. Velligan DI, Bow-Thomas CC, Huntzinger C, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 2000;157:1317-23.
53. Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis 2006;194:164-72.
54. Kraepelin E. Dementia praecox and paraphrenia. Barclay RM, trans. Huntington, New York: Krieger; 1971.
55. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-30.
56. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000;45:175-84.
57. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and non-deficit forms of schizophrenia: The concept. Am J Psychiatry 1988;145:578-83.
58. Miller DD, Tandon R. The biology and pathophysiology of negative symptoms. In: Keefe R, McEvoy J, eds. Negative symptoms of schizophrenia. Washington, DC: American Psychiatric Press; 2000:163-86.
59. Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985;11:440-52.
60. Meltzer HY, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986;6:329-38.
61. Erhart SM, Marder SR, Carpenter WT. Treatment of negative symptoms: Future prospects. Schizophr Bull 2006;32:234-7.
62. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis. J Clin Psychiatry 1997;58:538-46.
63. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
64. King DJ. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 1998;8:33-42.
65. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56:21-7.
66. Hirsch SR, Jolley A, Barnes T. Are depressive symptoms part of the schizophrenic syndrome? In: Delisi LE, ed. Depression in schizophrenia. Washington DC: American Psychiatric Press; 1990;25-37.
67. Mittal D, Davis CE, Depp C, et al. Correlates of health-related quality of well-being in older patients with schizophrenia. J Nerv Ment Dis 2006;194:335-40.
68. Norholm V, Bech P. Quality of life in schizophrenic patients: Association with depressive symptoms. Nord J Psychiatry 2006;60:32-7.
69. Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-10.
70. Siris SG. Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000;157:1379-9.
71. Siris S, Pollack S, Bermanzohn P, et al. Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia. Schizophr Res 2000;44:187-92.
72. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-28.
73. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006;31:2033-46.
74. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone. Biol Psychiatry 2002;51:972-8.
75. Harvey PD, Keefe RSE. Studies of cognitive change with novel antipsychotic treatment in schizophrenia. Am J Psychiatry 2001;158,176-84.
76. Keefe RS, Silva SG, Perkins DO, et al. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 1999;25:201-22.
77. Tandon R, Taylor SF, DeQuardo JR, et al. The cholinergic system in schizophrenia reconsidered. Neuropsychopharmacology 1999;22:S189-202.
78. Buchanan RW, Summerfelt A, Tek C, et al. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 2003;59:29-33.
79. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006;67(suppl 9):9-13.
80. Medalia A, Lim R. Treatment of cognitive dysfunction in psychiatric disorders. J Psychiatr Pract 2004;10:17-25.
81. Kern RS, Green MF, Mintz J, et al. Does "errorless learning" compensate for neurocognitive impairments in the work rehabilitation of persons with schizophrenia? Psychol Med 2003;33:433-42.
82. Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: Problems, prospects, and strategies. Schizophr Bull 1999;25:257-74.
83. Hogarty GE, Flesher S, Ulrich R, et al. Cognitive enhancement therapy for schizophrenia: Effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry 2004;61:866-76.
84. Fiszdon JM, Whelahan H, Bryson GJ, et al. Cognitive training of verbal memory using a dichotic listening paradigm: Impact on symptoms and cognition Acta Psychiatr Scand 2005;112:187-93.
85. Bell M, Bryson G, Wexler BE. Cognitive remediation of working memory deficits: Durability of training effects in severely impaired and less severely impaired schizophrenia. Acta Psychiatr Scand 2003;108:101-9.
86. Silverstein SM, Hatashita-Wong M, Solak BA, et al. Effectiveness of a two-phase cognitive rehabilitation intervention for severely impaired schizophrenia patients. Psychol Med 2005;35:829-37.
87. Pilling S, Bebbington P, Kuipers E, et al. Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychol Med 2002;32:782-91.
88. Meyer JM, Nasrallah HA, eds. Medical illness and schizophrenia. Washington, DC: American Psychiatric Press; 2003.
89. Meloni D, Miccinesi G, Bencini A, et al. Mortality among discharged psychiatric patients in Florence, Italy. Psychiatr Serv 2006;57:1474-81.
90. Miller BJ, Paschall CB 3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 2006;57:1482-7.
91. Salokangas RK, Honkonen T, Stengard E, et al. Mortality in chronic schizophrenia during decreasing number of psychiatric beds in Finland. Schizophr Res 2002;54:265-75.
92. Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003;178(suppl):S67-70.
93. Sokal J, Messias E, Dickerson FB, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004;192:421-7.
94. Jibson MD, Tandon R. An overview of antischizophrenic medications. In: Tandon R, ed. Managing schizophrenia: A comprehensive primer 2005. New York: McMahon Publishing; 2005.
95. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-72
96. and Diabetes Care 2004;27:596-601.
97. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49.
98. Covell NH, Jackson CT, Weissman EM. Health monitoring for patients who have schizophrenia: Summary of the Mount Sinai Conference Recommendations. Post Grad Med Special Report August 2006:20-6.
99. Weiden PJ. Switching in the era of atypical antipsychotics: An updated review. Post Grad Med Special Report August 2006:27-44.
100. Edlinger M, Baumgartner S, Eltanaihi-Furtmuller N, et al. Switching between second-generation antipsychotics: When and how? CNS Drugs 2005;19:27-42.
101. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia and schizoaffective disorder in general clinical practice. Schizophr Res 2006;84:77-89.
102. Weiden PJ. Preskorn SH, Fahnestock P, et al. A roadmap: Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness. J Clin Psychiatry 2006 (suppl) in press.
103. Newcomer JW. Second generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19(suppl 1):1-93.
104. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595-600.
105. Kopelowicz A, Liberman RP, Zarate R. Recent advances in social skills training for schizophrenia. Schizophr Bull 2006;32(1 suppl):S12-23.
106. Mueser KT, Clark RE, Haines M, et al.The Hartford study of supported employment for persons with severe mental illness. J Consult Clin Psychol 2004;72:479-90.
107. Cook JA, Leff HS, Blyler CR, et al. Results of a multisite randomized trial of supported employment interventions for individuals with severe mental illness. Arch Gen Psychiatry 2005;62:505-12.
108. Ziguras SJ, Stuart GW. A meta-analysis of the effectiveness of mental health case management over 20 years. Psychiatr Serv 2000;51:1410-21.
109. Aquila R, Weiden PJ, Emanuel M. Compliance and the rehabilitation alliance. J Clin Psychiatry 1999;60(suppl 19):23-7.
110. Burns BJ, Santos AB. Assertive community treatment: An update of randomized trials. Psychiatr Serv 1995;46:669-75.
111. Gold PB, Meisler N, Santos AB, et al. Randomized trial of supported employment integrated with assertive community treatment for rural adults with severe mental illness. Schizophr Bull 2006;32:378-95.
112. Perlick DA, Rosenheck RA, Kaczynski R, et al. Components and correlates of family burden in schizophrenia. Psychiatr Serv 2006;57:1117-25.
113. Dixon L, Lucksted A, Stewart B, et al. Outcomes of the peertaught 12-week Family-to-Family education program for severe mental illness. Acta Psychiatr Scand 2004;109:207-15.
114. Hazel NA, McDonell MG, Short RA, et al. Impact of multiple-family groups for outpatients with schizophrenia on caregivers' distress and resources. Psychiatr Serv 2004;55:35-41.
115. McFarlane WR, Dushay RA, Deakins SM, et al. Employment outcomes in family-aided assertive community treatment. Am J Orthopsychiatry 2000;70:203-14.
116. Goeree R, Farahati F, Burke N, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 2005;21:2017-28.
117. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9.
118. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006;39:161-70.
119. Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-9.
120. van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113: 91-5.
121. Bellack AS. Scientific and consumer models of recovery in schizophrenia: Concordance, contrasts, and implications. Schizophr Bull 2006;32:432-42.
122. Davidson L, Chinman M, Sells D, et al. Peer support among adults with serious mental illness: A report from the field. Schizophr Bull 2006;32:443-50.
123. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. DHEW publication # 76-338. Rockville, Maryland, ADAMHA, 1976.
124. Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale: Reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-9.
125. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000: 32-34.
126. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
127. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-6.
128. Dott SG, Weiden P, Hopwood P, et al. An innovative approach to clinical communication in schizophrenia. CNS Spectrums 2001;6:333-8.
129. Weiden PJ, Miller AL. Which side-effects really matter? Screening for common and distressing side-effects of antipsychotic medication. J Psychiatr Pract 2001;7:41-7.
130. Tandon R, Devellis RF, Han J, et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005;136:211-21.